 AUSTIN, Texas, July 09, 2021 GLOBE NEWSWIRE -- Molecular Templates, Inc. Nasdaq: MTEM, Molecular Templates or MTEM, a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ETBs, today announced the dosing of the first subject in a Phase 1 study investigating MT-6402 in patients with PD-L1-positive solid tumors. 